Loading...
A New Generation of Serotype Chimeric Infectivity-Enhanced Conditionally Replicative Adenovirals: The Safety Profile of Ad5/3-Δ24 in Advance of a Phase I Clinical Trial in Ovarian Cancer Patients
Conditionally replicative adenoviral (CRAd) virotherapy represents a promising therapeutic approach for cancer. We have demonstrated that a serotype chimeric adenoviral 5/3 fiber-knob modification achieves enhanced ovarian cancer infectivity, conditional replication, and oncolytic activity. This stu...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
Mary Ann Liebert, Inc.
2011
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3135257/ https://ncbi.nlm.nih.gov/pubmed/21171861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/hum.2010.180 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|